ARTEMIS Pharmaceuticals Company Profile

11:49 EDT 18th June 2018 | BioPortfolio

ARTEMIS Pharmaceuticals, based in Cologne Germany was founded in 1998 and has made significant advances to provide rapid, efficient and sophisticated techniques for the analysis of gene function in vertebrates.We are a wholly-owned subsidiary of Exelixis Inc., South San Francisco CA (NASDAQ: EXEL), but operate a distinct business model. Our activities are dedicated towards the provision of transgenic mouse generation services, tools and related licenses to the industrial and academic community. We operate on a fee for service basis and have a wide range of collaboration possibilities to provide solutions for our customers. Customers include Merck and Co. Inc., Bayer AG, Sanofi-Aventis, Biovitrum, EVOTEC Neurosciences, Regeneron Pharmaceuticals, Schering AG, Boehringer Ingelheim and a large number of other companies and universities.


Neurather Ring 1


Phone: 49 (0) 221-964 53-10
Fax: 49 (0) 221-964 53-21

News Articles [481 Associated News Articles listed on BioPortfolio]

Artemis new data on Artemisone shows potent inhibitor of human cytomegalovirus replication in preclinical assays

Artemis Therapeutics, Inc., a pharmaceutical company developing new therapies for the treatment of infectious diseases, including cytomegalovirus and malaria, announced that new data on its lead produ...

Artemis Health Announces HITRUST CSF Security Compliance

SALT LAKE CITY, April 2, 2018/PRNewswire/ -- Artemis Health, a benefits analytics software company, has completed a HITRUST CSF audit. The Health Information Trust Read more...

Eureka Therapeutics Closes $60 Million in Series D Financing to Advance Proprietary ARTEMIS™ T Cell Receptor Platform for Safer T Cell Therapies

Eureka Therapeutics, Inc., a clinical stage biotechnology company focused on improving the safety profile of T cell therapies and developing novel T cell therapies for the treatme...

Cutting Antiplatelet Costs in ACS Improves Therapy, Not Outcomes

Removing the copay on antiplatelet drugs given after ACS resulted in use of higher-potency agents and better patient adherence but didn't translate into fewer cardiac events, the ARTEMIS trial shows. ...

Eureka Therapeutics Announces Positive Preliminary Results of ET190L1-ARTEMISTM T-cell China Proof-of-Concept Human Clinical Study in Relapsed and Refractory (r/r) B-cell Lymphoma at ASCO Annual Meeting

No Cytokine Release Syndrome observed to date Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing nove...

Critical Contrast: Ironwood Pharmaceuticals

Ironwood Pharmaceuticals and Infinity Pharmaceuticals are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, d...

Semantic Interoperability of Medical Information Systems

A friend of mine sent me a link reporting about the Artemis Project, which is described as a A Semantic Web Service-based P2P Infrastructure for the Interoperability of Medical Information Systems. Qu...

Eureka Therapeutics closes $60mm Series D round

Eureka Therapeutics Inc. (developing T-cell immunotherapies for solid tumors) raised $60mm in its Series D round led by Acorn Pacific Ventures. GP Capital and all existing investors also participated....

Drugs and Medications [272 Associated Drugs and Medications listed on BioPortfolio]

Artemis alcohol-free antiseptic foam hand [Artemis Bio-Solutions Inc]

ARTEMIS ALCOHOL-FREE Antiseptic Foam Hand Soap

Artemis alcohol-free antiseptic foam hand sanitizer [Artemis Bio-Solutions Inc]

ARTEMIS ALCOHOL-FREE Antiseptic Foam Hand Sanitizer

Pur-wash [Niagara Pharmaceuticals Inc.]


Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

PubMed Articles [134 Associated PubMed Articles listed on BioPortfolio]

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Genetics of familial hypercholesterolemia: a tool for development of novel lipid lowering pharmaceuticals?

Familial hypercholesterolemia is characterized by high LDL cholesterol and an elevated risk to develop coronary heart disease. Mutations in LDL receptor-mediated cholesterol uptake are the main cause ...

Post-production handling and administration of protein pharmaceuticals and potential instability issues.

The safety and efficacy of protein pharmaceuticals depend not only on biological activity, but also on purity levels. Impurities may be process related due to limitations in manufacturing, or product ...

A General Strategy for Site-Selective Incorporation of Deuterium and Tritium into Pyridines, Diazines and Pharmaceuticals.

Methods to incorporate deuterium and tritium atoms into organic molecules are valuable for medicinal chemistry. The prevalence of pyridines and diazines in pharmaceuticals means that new ways to label...

Environmental concentrations of pharmaceuticals directly affect phytoplankton and effects propagate through trophic interactions.

Pharmaceuticals are found in freshwater ecosystems where even low concentrations in the range of ng Lmay affect aquatic organisms. In the current study, we investigated the effects of chronic exposure...

Clinical Trials [229 Associated Clinical Trials listed on BioPortfolio]

Clinical Study of ET190L1-ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma

This study is to determine the safety, including potential dose limiting toxicities, of ET190L1-ARTEMIS™ T cells and the duration of in vivo survival of ET190L1-ARTEMIS™ T cells in pat...

MIND: Artemis in the Removal of Intracerebral Hemorrhage

The primary objective of this multicenter randomized controlled study is to compare the safety and efficacy of minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Devi...

Study of ET190L1-ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma

This is a non-randomized, single arm, open-label, single institution, phase I study to determine the maximum tolerated dose (MTD) of ET190L1-ARTEMIS™ T cells in patients ≥ 18 years of ...

Measurements of Myocardial Relaxation Time by MRI During Respiration

Measurement of T2 transversal relaxation time by magnetic resonance has a major interest in cardiac imagery. It has been initially used for quantitative evaluation of heart viability and m...

(ARTEMIS-IPF)Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF

The ARTEMIS-IPF study is for people who have been diagnosed with IPF and are between 40-80 years of age. People who have been diagnosed early in the disease may be more responsive to treat...

Companies [1329 Associated Companies listed on BioPortfolio]

Artemis Health Group

Artemis is the nation’s leading provider of specialty-specific electronic medical record (EMR), workflow and mobile patient engagement solutions to help bridge the gap betwee...

ARTEMIS Pharmaceuticals

ARTEMIS Pharmaceuticals, based in Cologne Germany was founded in 1998 and has made significant advances to provide rapid, efficient and sophisticated techniques for the analysis of gene function in ve...

Artemis International, Inc.

ARTEMISPharmaceuticals GmbH

ARTEMIS has developed the ArteMice™ platform, a combination of rapid and sophisticated gene vector design, efficient and expert ES cell transfection techniques, novel blastocyst injection techniques...

Artemis Search

We have been recruiting in the biotechnology arena since 1987. We offer COntract recruitment, executive search and research services exclusiviely to the biotech industry.

More Information about "ARTEMIS Pharmaceuticals" on BioPortfolio

We have published hundreds of ARTEMIS Pharmaceuticals news stories on BioPortfolio along with dozens of ARTEMIS Pharmaceuticals Clinical Trials and PubMed Articles about ARTEMIS Pharmaceuticals for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ARTEMIS Pharmaceuticals Companies in our database. You can also find out about relevant ARTEMIS Pharmaceuticals Drugs and Medications on this site too.

Quick Search


Relevant Topics

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Corporate Database Quicklinks

Searches Linking to this Company Record